Next-Wave Obesity Therapeutics & Drug Development Summit Europe 2026

From Discovery to Delivery: Transforming Obesity Care Through Next-Generation Therapeutics

Welcome to The Next-Wave Obesity Therapeutics & Drug Development Summit Europe 2026 - The Next-Wave Obesity Therapeutics & Drug Development Summit Europe 2026 unites global R&D leaders, biotech innovators, clinicians, and investors driving the next era of obesity and metabolic disease treatment.

From peptide and RNA therapeutics to small molecules and multi-agonist strategies, this summit bridges cutting-edge science and commercial execution — turning breakthrough research into accessible, effective therapies.

---

Who Should Attend

• Obesity & Metabolic Disease Researchers
• Pharma & Biotech R&D Executives
• Drug Development, Clinical & Regulatory Leaders
• Market Access & Commercial Strategy Professionals
• Endocrinologists, Clinician-Scientists & KOLs
• Investors & Business Development Leaders

---

Industries Represented

• Biopharmaceutical & Biotech Companies
• Peptide, RNA & Metabolic Therapeutic Developers
• CROs & CDMOs
• Clinical Trial Design & Data Analytics Firms
• Market Access & Health Economics Consultancies
• Regulatory Agencies & Policy Experts

---

Key Themes

Next-Generation Targets in Obesity Therapeutics

• Dual, triple, and multi-agonist strategies (GLP-1, GIP, glucagon, amylin)
• Central nervous system and appetite-regulation pathways
• RNA, gene-based, and peptide innovation for metabolic modulation

Clinical Development & Translational Science

• Translating mechanism-based research into clinical success
• Biomarker-driven patient stratification and endpoint design
• Long-term safety, tolerability, and efficacy management

Manufacturing & Drug Delivery Innovation

• Scaling oral, injectable, and implantable formulations
• Overcoming cold-chain and stability challenges
• Partnerships with CDMOs for rapid, compliant production

Regulatory Strategy & Market Access

• EMA, FDA, and MHRA guidance for obesity indications
• Leveraging expedited pathways for metabolic diseases
• Evidence generation to meet HTA and payer expectations

Commercialisation & Strategic Partnerships

• Pricing, licensing, and alliance models in obesity therapeutics
• Go-to-market planning for high-growth metabolic portfolios
• Pharma–biotech collaborations for co-development and launch

Digital Health, Real-World Data & Long-Term Outcomes

• Integrating wearables and ePROs in obesity trials
• Using AI and RWE to strengthen post-approval value demonstration
• Building sustainable, data-driven obesity care ecosystems